Medicare patients with cancer often receive aggressive treatment over supportive care

Many Medicare patients with advanced cancer receive potentially aggressive treatment at the expense of supportive care, according to a study that analyzed Medicare records.

ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer

MADRID — Disease-free survival (DFS) in resectable ALK-positive non-small cell lung cancer (NSCLC) improved by 76% with adjuvant alectinib (Alecensa) compared with chemotherapy, according to

October 25, 2023

IMIDomics to license TNAX’s drug candidate for IMIDs

IMIDomics will expedite the development of the antibody to exploit its potential across various immune-mediated inflammatory diseases. Credit: National Cancer Institute on Unsplash. IMIDomics has entered

September 7, 2023

Growing ‘Medical Freedom’ Movement Poses Challenge for Public Health

The “medical freedom” movement that has gained traction in the U.S. since the COVID-19 pandemic could continue to push public health statistics in a troubling

January 11, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.